Abstract

Research Article

A Prospective Observational Study on Neurotoxicity of Chemotherapy - A Critical Analysis

Syeda Zaineb Kubra Hussaini*, Swapna Jilla, Gumdal Vishesh, Peddapalegani Pallavardhan, Kalidindi Deekshita, Kashadatla Rashmitha, Kavuri Chaitanya and Kommu Kathyayani

Published: 02 April, 2024 | Volume 8 - Issue 1 | Pages: 022-029

Background: Cancer treatment frequently depends on the intricate and potent effects that are acknowledged for their potential to save lives. Chemotherapy can have adverse effects on both the central and peripheral nervous systems, posing significant challenges.
Objective: 
•    To assess the causative agent, development, and timing of occurrence.
•    To improve management of neurological complications.
•    To discriminate the iatrogenic effects of cancer therapy and neurological progression.
Method: A prospective observational study was conducted in a hospital setting, focusing on the neurotoxic effects of chemotherapy in cancer patients over a span of six months. The research involved participants from both the oncology in-patient and daycare departments. After obtaining informed consent, individuals in the study population were interviewed to gather information about any neurological symptoms they encountered following their chemotherapy sessions.
Results and discussion: Within our study population, a predominant 67% comprised female patients, while male patients constituted 33%. Of the total participants, 66% reported experiencing neurological symptoms. Among these symptoms, the majority of patients encountered sensations such as tingling, numbness, and a burning sensation. Other reported symptoms included headaches, distal weakness, myalgia, seizures, and ataxia.
Conclusion: In this current study, 66% of the study population encountered neurological side effects. Generally, the presence of comorbidities, vitamin deficiencies, and advanced age can significantly contribute to the development of peripheral neuropathy. Depending on the severity of neuropathy, recommendations for interventions include the prescription of vitamin supplements, calcium supplements, duloxetine, and pregabalin.

Read Full Article HTML DOI: 10.29328/journal.jro.1001061 Cite this Article Read Full Article PDF

Keywords:

Cancer; Chemotherapy; Peripheral neuropathy; Paraesthesia; Neurotoxicity

References

  1. Ganz PA, Dougherty PM. Painful Hands and Feet After Cancer Treatment: Inflammation Affecting the Mind-Body Connection. J Clin Oncol. 2016 Mar 1;34(7):649-52. doi: 10.1200/JCO.2015.64.7479. Epub 2015 Dec 23. PMID: 26700128. An updated expert opinion on recent advances regarding chemotherapy –related neurotoxicity, underscoring the important role of inflammation in cognitive dysfunction, and peripheral neuropathy, both linked to neuroinflammation as well as genetic susceptibility to persistent inflammation andbehavioral symptoms. The authors also highlight that the symptoms of chemotherapy neurotoxicity can now be measured with a wide variety of well-validated self-report tools i.e. patient-reported outcomes.
  2. Nudelman KN, McDonald BC, Wang Y, Smith DJ, West JD, O'Neill DP, Zanville NR, Champion VL, Schneider BP, Saykin AJ. Cerebral Perfusion and Gray Matter Changes Associated with Chemotherapy-Induced Peripheral Neuropathy. J Clin Oncol. 2016 Mar 1;34(7):677-83. doi: 10.1200/JCO.2015.62.1276. Epub 2015 Nov 2. PMID: 26527786; PMCID: PMC4822503. Longitudinal relationship between chemotherapy-induced peripheral neuropathy (CIPN) symptoms and brain perfusion changes in patients with breast cancer. CIPN symptoms were positively associated with cerebral perfusion in the right superior frontal gyrus and cingulate gyrus, regions associated with pain processing.
  3. Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology. 2012 Jan 27;291(1-3):1-9. doi: 10.1016/j.tox.2011.10.019. Epub 2011 Nov 3. PMID: 22079234.
  4. Jansen C, Miaskowski C, Dodd M, Dowling G, Kramer J. Potential mechanisms for chemotherapy-induced impairments in cognitive function. Oncol Nurs Forum. 2005 Nov 3;32(6):1151-63. doi: 10.1188/05.ONF.1151-1163. PMID: 16270111.
  5. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 2003;63(15):1549-63. doi: 10.2165/00003495-200363150-00003. PMID: 12887262.
  6. Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013 Nov-Dec;63(6):419-37. doi: 10.3322/caac.21204. PMID: 24590861.
  7. Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015 Apr;75(4):659-70. doi: 10.1007/s00280-014-2607-5. Epub 2015 Jan 18. PMID: 25596818; PMCID: PMC4365177.
  8. Eckhoff L, Knoop AS, Jensen MB, Ejlertsen B, Ewertz M. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat. 2013 Nov;142(1):109-18. doi: 10.1007/s10549-013-2728-2. Epub 2013 Oct 17. PMID: 24132874.
  9. Brewer JR, Morrison G, Dolan ME, Fleming GF. Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecol Oncol. 2016 Jan;140(1):176-83. doi: 10.1016/j.ygyno.2015.11.011. Epub 2015 Nov 7. PMID: 26556766; PMCID: PMC4698212.
  10. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012 Sep;14 Suppl 4(Suppl 4):iv45-54. doi: 10.1093/neuonc/nos203. PMID: 23095830; PMCID: PMC3480245.
  11. Zhang S. Chemotherapy-induced peripheral neuropathy and rehabilitation: A review. Semin Oncol. 2021 Jun;48(3):193-207. doi: 10.1053/j.seminoncol.2021.09.004. Epub 2021 Sep 22. PMID: 34607709.
  12. Lee GD, Longo DL, Wang Y, Rifkind JM, Abdul-Raman L, Mamczarz JA, Duffy KB, Spangler EL, Taub DD, Mattson MP, Ingram DK. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res. 2006 Jan 1;12(1):198-205. doi: 10.1158/1078-0432.CCR-05-1286. PMID: 16397043.
  13. Taillibert S, Le Rhun E, Chamberlain MC. Chemotherapy-Related Neurotoxicity. Curr Neurol Neurosci Rep. 2016 Sep;16(9):81. doi: 10.1007/s11910-016-0686-x. PMID: 27443648.
  14. Was H, Borkowska A, Bagues A, Tu L, Liu JYH, Lu Z, Rudd JA, Nurgali K, Abalo R. Mechanisms of Chemotherapy-Induced Neurotoxicity. Front Pharmacol. 2022 Mar 28;13:750507. doi: 10.3389/fphar.2022.750507. PMID: 35418856; PMCID: PMC8996259.
  15. Beijers AJ, Jongen JL, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med. 2012 Jan;70(1):18-25. PMID: 22271810.
  16. Banach M, Juranek JK, Zygulska AL. Chemotherapy-induced neuropathies—a growing problem for patients and health care providers. Brain Behav. 2017; 7. doi: 10.1002/BRB3.558.
  17. Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, Sundar R, Chan A, Ng TR, Suen LKP, Chan CW, Yorke J, Lopez V. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav. 2019 Jun;9(6):e01312. doi: 10.1002/brb3.1312. Epub 2019 May 7. PMID: 31063261; PMCID: PMC6576180.
  18. Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013 Nov-Dec;63(6):419-37. doi: 10.3322/caac.21204. PMID: 24590861.
  19. Catalano M, Ramello M, Conca R, Aprile G, Petrioli R, Roviello G. Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer. Oncology. 2022;100(7):384-391. doi: 10.1159/000524868. Epub 2022 May 12. PMID: 35551139.
  20. Ewertz M, Qvortrup C, Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol. 2015 May;54(5):587-91. doi: 10.3109/0284186X.2014.995775. Epub 2015 Mar 9. PMID: 25751757.
  21. Gutiérrez-Gutiérrez G, Sereno M, Miralles A, Casado-Sáenz E, Gutiérrez-Rivas E. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol. 2010 Feb;12(2):81-91. doi: 10.1007/S12094-010-0474-z. PMID: 20156778.
  22. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006 Feb;33(1):15-49. doi: 10.1053/j.seminoncol.2005.12.010. PMID: 16473643.
  23. Troy L. Cisplatin-Based Therapy: a Neurological and Neuropsychological Review. Psychooncology. 2000; 9: 29-39.
  24. Gorzelak-Magiera A, Bobola A, Robek A, Krzystanek E, Gisterek I. Selected neurological complications of oncological treatment — literature overview. Oncology in Clinical Practice. 2022. doi: 10.5603/OCP.2022.0032.
  25. Argyriou AA, Bruna J, Genazzani AA, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol. 2017 Aug;13(8):492-504. doi: 10.1038/nrneurol.2017.88. Epub 2017 Jun 30. PMID: 28664909.
  26. Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci. 2019 Mar 22;20(6):1451. doi: 10.3390/ijms20061451. PMID: 30909387; PMCID: PMC6471666.
  27. Geber C, Breimhorst M, Burbach B, Egenolf C, Baier B, Fechir M, Koerber J, Treede RD, Vogt T, Birklein F. Pain in chemotherapy-induced neuropathy--more than neuropathic? Pain. 2013 Dec;154(12):2877-2887. doi: 10.1016/j.pain.2013.08.028. Epub 2013 Aug 30. PMID: 23999056.
  28. Grewal J, Grewal HK, Forman AD. Seizures and epilepsy in cancer: etiologies, evaluation, and management. Curr Oncol Rep. 2008 Jan;10(1):63-71. doi: 10.1007/s11912-008-0010-2. PMID: 18366962.
  29. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006 Apr 1;24(10):1633-42. doi: 10.1200/JCO.2005.04.0543. PMID: 16575015.
  30. Kish JA, Ensley JF, Jacobs J, Weaver A, Cummings G, Al-Sarraf M. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer. 1985 Dec 15;56(12):2740-4. doi: 10.1002/1097-0142(19851215)56:12<2740::aid-cncr2820561203>3.0.co;2-y. PMID: 3902199.
  31. Ostrom QT, Gittleman H, de Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R, Stearns DS, Wolff JE, Liu M, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol. 2016 Jan;18 Suppl 1(Suppl 1):i1-i50. doi: 10.1093/neuonc/nov297. PMID: 26705298; PMCID: PMC4690545.
  32. Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist. 2008 Dec;13(12):1285-95. doi: 10.1634/theoncologist.2008-0130. Epub 2008 Nov 19. PMID: 19019972.
  33. Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology. 2012 Jan 27;291(1-3):1-9. doi: 10.1016/j.tox.2011.10.019. Epub 2011 Nov 3. PMID: 22079234.
  34. Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015 Apr;75(4):659-70. doi: 10.1007/s00280-014-2607-5. Epub 2015 Jan 18. PMID: 25596818; PMCID: PMC4365177.
  35. Hansen N. Drug-induced encephalopathy. In: Tanasescu R, editor. Miscellanea on encephalopathies a second look. InTech. 2012; 39-60.
  36. DeAngelis LM, Posner JB. Side effects of chemotherapy. In: Neurologic complications of cancer, 2nd. New York, Oxford University Press. 2009; 447.
  37. Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan RB, Panetta JC, Krull KR, Inaba H, Rubnitz JE, Metzger ML, Howard SC, Ribeiro RC, Cheng C, Reddick WE, Jeha S, Sandlund JT, Evans WE, Pui CH, Relling MV. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014 Mar 20;32(9):949-59. doi: 10.1200/JCO.2013.53.0808. Epub 2014 Feb 18. PMID: 24550419; PMCID: PMC3948096.
  38. Li SH, Chen WH, Tang Y, Rau KM, Chen YY, Huang TL, Liu JS, Huang CH. Incidence of ischemic stroke post-chemotherapy: a retrospective review of 10,963 patients. Clin Neurol Neurosurg. 2006 Feb;108(2):150-6. doi: 10.1016/j.clineuro.2005.03.008. Epub 2005 Apr 25. PMID: 16412836.
  39. Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol. 2008 Jun;6(6):455-67. PMID: 18567992.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?